MINNETONKA, Minn., May 4, 2011 /PRNewswire/ — American
Medical Systems® (AMS) (NASDAQ: AMMD), a leading provider
of world-class devices and therapies for male and female pelvic
health, today announced it has received clearance from the Japanese
Ministry of Health, Labor and Welfare (MHLW) to market and
distribute its GreenLight HPS® laser therapy system for the
treatment of Benign Prostatic Hyperplasia (BPH), or enlarged
prostate, in Japan.
As the worldwide market leader in laser BPH treatment, AMS’
GreenLight provides treatment with fewer side effects than TURP,
improving clinical outcomes and patient safety for individuals with
mild to severe BPH symptoms. The system is designed to enable the
treatment of a wide range of gland sizes, as well as for patients
on anti-coagulation therapy.
“We are thrilled to offer this leading-edge technology to
provide a safer and less-invasive BPH treatment for Japanese men,”
said Mike Ryan, AMS’ vice president and general manager for Asia
Pacific, Latin America and Canada. “The approval of GreenLight
represents a significant opportunity in Japan, as BPH is one of the
most common diseases among older Japanese men, with the number of
treatment procedures growing by over 4 percent each year.”
GreenLight’s high performance system (HPS) delivers efficient
procedure times and the ability to treat large glands. The system
will be offered in Japan through an exclusive distribution
agreement with MC Medical, Inc., a subsidiary of Mitsubishi
Corporation and a leading supplier of minimally invasive medical
devices and supplies in Japan.
“Over 500,000 patients worldwide have been treated with
GreenLight and with nearly 4 million men suffering from moderate to
severe BPH symptoms in Japan, this is a great opportunity for us to
help a growing population,” Ryan said. “Not only does this
expansion strengthen AMS’ global presence but it also all
‘/>”/>
SOURCE
